ASTRO Corrects Media Misinformation on Breast Cancer Treatment Options

Strategic Insights -

ASTRO, the leading organization representing radiation oncologists, has issued a statement correcting media misinformation on breast cancer treatment options. The organization has expressed concern over an NBC News story that presented inaccurate and misleading information on intraoperative radiation therapy (IORT) for breast cancer. ASTRO's Breast Cancer Resource Panel has clarified the current data on breast cancer treatment, emphasizing the importance of evidence-based medicine and patient trust.

Key Takeaways:

  • ASTRO's guideline development process involves rigorous methodology, independent data review, multidisciplinary input, and thorough peer review.
  • The ASTRO guideline for partial breast irradiation was developed by a multidisciplinary team of radiation, surgical, and medical oncologists, a medical physicist, and a patient representative.
  • ASTRO guidelines are published based on robust data evaluating clinical data and patient outcomes, without considering financial implications.
  • The organization recommends shorter courses of radiation therapy for patients, including those with breast cancer, as evident in the recent ASTRO/ASCO/SSO guideline on post-mastectomy radiation therapy.
  • Accelerated partial breast irradiation (APBI) is a valuable treatment option for many patients that offers a shorter course of radiation while maintaining oncologic efficacy and safety.
  • IORT has not been proven to have the value of other methods of partial breast irradiation.
  • The TARGIT trial has only published results with a median follow-up of less than three years for the full pre-specified population, which is insufficient to assess long-term recurrence and toxicity outcomes.
  • The ELIOT trial showed significantly higher local recurrence rates with IORT compared to WBI, even when re-analyzed for patients with very low risk disease.
  • Technical concerns with IORT, including the use of a proprietary device and smaller target volumes, may contribute to inferior outcomes.
  • Approximately 20% of patients in the TARGIT trial required subsequent WBI, introducing additional side effect risks and undermining the premise of a single-treatment approach.
  • Long-term toxicity, such as breast fibrosis, is significantly higher in patients that receive IORT+WBI compared to IORT alone (38% vs. 6%).

Statistics:

  • Over 10,000 patients have been included in randomized controlled trials (RCTs) supporting EBRT and brachytherapy APBI, with up to 10 years of follow-up.
  • The TARGIT trial has a median follow-up of less than three years for the full pre-specified population.
  • Approximately 20% of patients in the TARGIT trial required subsequent WBI.
  • Breast fibrosis is present in 38% of patients receiving IORT+WBI and 6% of patients receiving IORT alone.

Sources:

  • American Society for Radiation Oncology (ASTRO)
  • NBC News
  • ASTRO/ASCO/SSO guideline on post-mastectomy radiation therapy
  • American Society of Breast Surgeons
  • Society of Surgical Oncology
  • Canadian Association of Radiation Oncology
  • European Society for Radiotherapy and Oncology
  • Royal Australian and New Zealand College of Radiologists